现代泌尿外科杂志2024,Vol.29Issue(3) :248-252.DOI:10.3969/j.issn.1009-8291.2024.03.010

CMTM6、RASAL2在前列腺癌组织中的表达及其与临床病理特征及预后的关系

Expressions of CMTM6 and RASAL2 in prostate cancer tissues and their relationship with clinicopathological features and prognosis

刘太阳 李杰 沈雁冰 桂琦 黄雪强 文秀华
现代泌尿外科杂志2024,Vol.29Issue(3) :248-252.DOI:10.3969/j.issn.1009-8291.2024.03.010

CMTM6、RASAL2在前列腺癌组织中的表达及其与临床病理特征及预后的关系

Expressions of CMTM6 and RASAL2 in prostate cancer tissues and their relationship with clinicopathological features and prognosis

刘太阳 1李杰 1沈雁冰 1桂琦 1黄雪强 1文秀华1
扫码查看

作者信息

  • 1. 驻马店市中心医院泌尿外科,河南驻马店 463000
  • 折叠

摘要

目的 分析含家族成员6的趋化因子样奇迹跨膜结构域(CMTM6)、大鼠肉瘤蛋白活化因子2(RASAL2)在前列腺癌组织中的表达,分析其与前列腺癌患者临床病理特征及预后的关系.方法 收集驻马店市中心医院泌尿外科2018年2月-2020年2月手术切除的前列腺癌组织及癌旁正常组织各80例.免疫组化法测定前列腺癌组织和癌旁组织中CMTM6、RASAL2阳性表达情况;分析其与前列腺癌患者临床病理特征的关系;使用Kaplan-Meier法绘制前列腺癌患者生存曲线;多因素Cox回归分析前列腺癌患者预后的影响因素.结果 CMTM6在前列腺癌组织中的阳性表达率为67.50%,显著高于癌旁组织38.75%(x2=13.277,P<0.001).RASAL2在前列腺癌组织中的阳性表达率为47.50%,显著低于癌旁组织73.75%(x2=11.546,P=0.001).CMTM6、RASAL2表达与前列腺癌患者年龄、肿瘤大小、组织分化程度无明显相关性(P>0.05),与TNM分期、Gleason评分、淋巴结转移、术前前列腺特异性抗原(PSA)水平相关(P<0.05).Kaplan-Meier生存曲线结果显示:CMTM6阳性表达患者 3 年存活率为 61.11%(33/54),显著低于 CMTM6 阴性表达患者[88.46%(23/26),(x2=5.940,P=0.015)];RASAL2阳性表达患者3年存活率为81.85%(31/38),显著高于RASAL2阴性表达患者[59.52%(25/42),(x2=4.887,P=0.027)].Cox多因素回归分析结果显示:Gleason评分、淋巴结转移、术前PSA水平、CMTM6及RASAL2的表达情况均是影响前列腺癌患者预后的独立因素(P<0.05).结论 前列腺癌组织中CMTM6阳性表达率显著高于癌旁组织,RASAL2阳性表达率显著低于癌旁组织,二者可能与前列腺癌患者临床病理特征及预后相关.

Abstract

Objective To investigate the expressions of containing CKLF like MARVEL transmembrane domain gene 6(CMTM6)and ras protein activator like 2(RASAL2)in prostate cancer tissues,and to analyze the relationships between the above factors and the clinicopathological characteristics and prognosis of prostate cancer patients.Methods The prostate cancer tissues and adjacent tissues of 80 prostate cancer patients admitted to Zhumadian City Center Hospital during Feb.2018 and Feb.2020 were collected.Expressions of CMTM6 and RASAL2 were detected with immunohistochemical method.The relationship between the expressions of CMTM6 and RASAL2 and the clinical pathological characteristics of prostate cancer were analyzed.The survival curve was plotted with Kaplan-Meier method.The prognostic factors were analyzed with multivariate Cox regression.Results The positive expression rate of CMTM6 in prostate cancer tissues was 67.50%,which was obviously higher than 38.75%in adjacent tissues(x2=13.277,P<0.001).The positive expression rate of RASAL2 in prostate cancer tissues was 47.50%,which was obviously lower than 73.75%in adjacent tissues(x2=11.546,P=0.001).The expressions of CMTM6 and RASAL2 were not related to patients'age,tumor size and tissue differentiation(P>0.05),but to TNM staging,Gleason score,lymph node metastasis and preoperative PSA level(P<0.05).Survival curve showed that the 3-year survival rate of positive CMTM6 expression patients was 61.11%(33/54),which was obviously lower than that of negative patients,which was 88.46%(23/26)(x2=5.940,P=0.015).The 3-year survival rate of positive RASAL2 expression patients was 81.85%(31/38),which was obviously higher than that of negative patients,which was 59.52%(25/42)(x2=4.887,P=0.027).Cox multivariate regression showed that Gleason score,lymph node metastasis,preoperative PSA level,CMTM6,and RASAL2 were independent influencing factors of prognosis(P<0.05).Conclusion The positive expression rate of CMTM6 in prostate cancer tissues is significantly higher than that in paracancer tissues,while the positive expression rate of RASAL2 in prostate cancer tissues is significantly lower than that in paracancer tissues.Both CMTM6 and RASAL2 are closely related to the clinical pathological characteristics and prognosis of prostate cancer patients,and may provide reference for the prognosis.

关键词

前列腺癌/含家族成员6的趋化因子样奇迹跨膜结构域(CMTM6)/大鼠肉瘤蛋白活化因子2(RASAL2)/病理特征/3年存活率

Key words

prostate cancer/CMTM6/RASAL2/pathological features/3-year survival rate

引用本文复制引用

出版年

2024
现代泌尿外科杂志
西安交通大学

现代泌尿外科杂志

CSTPCD
影响因子:1.106
ISSN:1009-8291
参考文献量20
段落导航相关论文